OmniStar Financial Group Inc. Has $769,000 Stake in Johnson & Johnson (NYSE:JNJ)

OmniStar Financial Group Inc. cut its stake in shares of Johnson & Johnson (NYSE:JNJ) by 48.5% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 4,719 shares of the company’s stock after selling 4,444 shares during the quarter. OmniStar Financial Group Inc.’s holdings in Johnson & Johnson were worth $769,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. Inspire Advisors LLC acquired a new position in shares of Johnson & Johnson in the third quarter worth approximately $219,000. Intergy Private Wealth LLC acquired a new position in shares of Johnson & Johnson in the 3rd quarter worth approximately $200,000. Aspiriant LLC boosted its stake in shares of Johnson & Johnson by 9.9% in the 3rd quarter. Aspiriant LLC now owns 23,211 shares of the company’s stock valued at $3,761,000 after purchasing an additional 2,085 shares during the last quarter. Trust Point Inc. increased its position in shares of Johnson & Johnson by 3.5% during the third quarter. Trust Point Inc. now owns 22,266 shares of the company’s stock worth $3,608,000 after buying an additional 757 shares during the period. Finally, Aaron Wealth Advisors LLC raised its stake in Johnson & Johnson by 8.0% during the third quarter. Aaron Wealth Advisors LLC now owns 19,189 shares of the company’s stock worth $3,110,000 after buying an additional 1,420 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Stock Up 0.4 %

Johnson & Johnson stock opened at $165.13 on Friday. Johnson & Johnson has a fifty-two week low of $143.13 and a fifty-two week high of $168.85. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.85 and a current ratio of 1.07. The firm’s 50-day simple moving average is $162.98 and its 200 day simple moving average is $154.71. The stock has a market cap of $397.41 billion, a PE ratio of 10.29, a price-to-earnings-growth ratio of 2.65 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share for the quarter, topping analysts’ consensus estimates of $2.21 by $0.21. The firm had revenue of $22.47 billion for the quarter, compared to the consensus estimate of $22.17 billion. Johnson & Johnson had a return on equity of 36.60% and a net margin of 46.34%. The company’s revenue was up 5.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.66 EPS. Research analysts predict that Johnson & Johnson will post 10 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Tuesday, November 26th will be paid a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.00%. The ex-dividend date of this dividend is Tuesday, November 26th. Johnson & Johnson’s payout ratio is 30.92%.

Insider Buying and Selling

In related news, VP Robert J. Decker sold 5,635 shares of the firm’s stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $165.06, for a total transaction of $930,113.10. Following the completion of the sale, the vice president now owns 18,973 shares in the company, valued at approximately $3,131,683.38. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 0.16% of the stock is owned by insiders.

Analyst Ratings Changes

A number of brokerages have weighed in on JNJ. The Goldman Sachs Group decreased their price target on Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating for the company in a report on Friday, July 19th. Wells Fargo & Company lifted their target price on Johnson & Johnson from $163.00 to $166.00 and gave the stock an “equal weight” rating in a report on Wednesday. Royal Bank of Canada boosted their price target on Johnson & Johnson from $178.00 to $181.00 and gave the company an “outperform” rating in a research note on Wednesday. Morgan Stanley lifted their price objective on shares of Johnson & Johnson from $169.00 to $175.00 and gave the company an “equal weight” rating in a research note on Wednesday. Finally, TD Cowen cut their target price on shares of Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating on the stock in a research note on Thursday, July 18th. Six research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Johnson & Johnson has an average rating of “Moderate Buy” and a consensus target price of $175.93.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.